Goldman Sachs’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.9K | Buy |
43,947
+7,995
| +22% | +$5.46K | ﹤0.01% | 6347 |
|
|
2025
Q4 | $23K | Sell |
35,952
-24,600
| -41% | -$18.9K | ﹤0.01% | 6336 |
|
|
2025
Q3 | $56.6K | Buy |
60,552
+13,756
| +29% | +$13.5K | ﹤0.01% | 6160 |
|
|
2025
Q2 | $59.9K | Sell |
46,796
-15,866
| -25% | -$15.9K | ﹤0.01% | 5888 |
|
|
2025
Q1 | $62.7K | Buy |
62,662
+37,519
| +149% | +$39.5K | ﹤0.01% | 5854 |
|
|
2024
Q4 | $22.9K | Buy |
+25,143
| New | +$24.7K | ﹤0.01% | 5889 |
|
|
2023
Q2 | – | Sell |
-15,365
| Closed | -$51.8K | – | 5797 |
|
|
2023
Q1 | $51.8K | Buy |
+15,365
| New | +$46.1K | ﹤0.01% | 5547 |
|
|
2022
Q4 | – | Sell |
-11,618
| Closed | -$16K | – | 6022 |
|
|
2022
Q3 | $16K | Sell |
11,618
-44,096
| -79% | -$86.1K | ﹤0.01% | 5967 |
|
|
2022
Q2 | $122K | Sell |
55,714
-243,163
| -81% | -$558K | ﹤0.01% | 5807 |
|
|
2022
Q1 | $954K | Buy |
298,877
+168,712
| +130% | +$604K | ﹤0.01% | 4857 |
|
|
2021
Q4 | $546K | Buy |
130,165
+43,115
| +50% | +$242K | ﹤0.01% | 5312 |
|
|
2021
Q3 | $707K | Sell |
87,050
-3,842
| -4% | -$31.2K | ﹤0.01% | 4987 |
|
|
2021
Q2 | $686K | Buy |
90,892
+22,631
| +33% | +$191K | ﹤0.01% | 5020 |
|
|
2021
Q1 | $593K | Sell |
68,261
-201,501
| -75% | -$1.92M | ﹤0.01% | 4994 |
|
|
2020
Q4 | $2.15M | Buy |
269,762
+70,967
| +36% | +$594K | ﹤0.01% | 3669 |
|
|
2020
Q3 | $1.59M | Buy |
198,795
+11,407
| +6% | +$103K | ﹤0.01% | 3737 |
|
|
2020
Q2 | $1.85M | Buy |
187,388
+111,713
| +148% | +$1.03M | ﹤0.01% | 3511 |
|
|
2020
Q1 | $585K | Buy |
75,675
+34,176
| +82% | +$173K | ﹤0.01% | 4116 |
|
|
2019
Q4 | $160K | Buy |
41,499
+27,985
| +207% | +$122K | ﹤0.01% | 4947 |
|
|
2019
Q3 | $68K | Buy |
13,514
+2,641
| +24% | +$15.4K | ﹤0.01% | 5014 |
|
|
2019
Q2 | $72K | Sell |
10,873
-3,052
| -22% | -$21K | ﹤0.01% | 4980 |
|
|
2019
Q1 | $105K | Sell |
13,925
-18,606
| -57% | -$145K | ﹤0.01% | 4922 |
|
|
2018
Q4 | $262K | Buy |
32,531
+9,006
| +38% | +$89.4K | ﹤0.01% | 4695 |
|
|
2018
Q3 | $303K | Buy |
23,525
+13,044
| +124% | +$164K | ﹤0.01% | 4708 |
|
|
2018
Q2 | $119K | Sell |
10,481
-31,532
| -75% | -$299K | ﹤0.01% | 5161 |
|
|
2018
Q1 | $296K | Buy |
42,013
+19,492
| +87% | +$147K | ﹤0.01% | 4789 |
|
|
2017
Q4 | $146K | Buy |
+22,521
| New | +$143K | ﹤0.01% | 5569 |
|
|
2016
Q1 | – | Sell |
-22,941
| Closed | -$128K | – | 7110 |
|
|
2015
Q4 | $128K | Buy |
22,941
+3,691
| +19% | +$25.1K | ﹤0.01% | 6037 |
|
|
2015
Q3 | $121K | Buy |
+19,250
| New | +$128K | ﹤0.01% | 6367 |
|
Other funds holding CTSO
AC
VCM
SC
CM
SIG
VFT
Goldman Sachs's CTSO Position: Q1 2026 in Review
Goldman Sachs increased its Cytosorbents Corp (CTSO) stake by 22% in Q1 2026, buying an estimated $5.46K and bringing the position to 43,947 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6347.
Goldman Sachs first reported a position in CTSO in Q3 2015 and has held it in 29 quarters since. The position peaked at $2.15M in Q4 2020. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.
- Goldman Sachs held 43,947 shares of Cytosorbents Corp worth $24.9K as of Q1 2026.
- Goldman Sachs bought 7,995 Cytosorbents Corp shares in Q1 2026, an estimated $5.46K.
- Cytosorbents Corp made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6347 holding.
- Goldman Sachs first reported a position in Cytosorbents Corp in Q3 2015 and has held it in 29 quarters since.
- Goldman Sachs's Cytosorbents Corp position peaked at $2.15M in Q4 2020.
- 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.